Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

@article{Petrylak2004DocetaxelAE,
  title={Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.},
  author={Daniel Peter Petrylak and Catherine M. Tangen and Maha H A Hussain and Primo N. Lara and Jeffrey A. Jones and Mary Ellen Taplin and Patrick A. Burch and Donna L. Berry and Carol Moinpour and Manish Kohli and Mitchell C. Benson and Eric Jay Small and D. Vijaya Raghavan and E. David Crawford},
  journal={The New England journal of medicine},
  year={2004},
  volume={351 15},
  pages={1513-20}
}
BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer. METHODS We randomly assigned 770 men to one of two treatments, each given in 21-day cycles: 280 mg of estramustine three times daily on days 1 through 5, 60 mg of docetaxel per square meter of body-surface area on… CONTINUE READING